Uremic Toxin-Targeting as a Therapeutic Strategy for Preventing Cardiorenal Syndrome

Area of Science:

• Nephrology
• Cardiology
• Toxicology

Background:

• Chronic kidney disease (CKD) is a global health issue with high rates of cardiovascular disease (CVD) comorbidity.
• A complex interplay, termed cardiorenal syndrome, links CKD and CVD progression.
• Accumulated uremic toxins due to impaired renal excretion are key contributors to this syndrome.

Purpose of the Study:

• To elucidate the molecular mechanisms by which specific uremic toxins contribute to cardiovascular disease.
• To highlight the role of asymmetric dimethylarginine (ADMA), advanced glycation endproducts (AGE), and trimethylamine N-oxide (TMAO) in cardiorenal syndrome.
• To explore the potential interrelationships between these major uremic toxins in disease pathogenesis.

Main Methods:

• Review of existing literature on uremic toxins and their impact on cardiovascular and renal systems.
• Analysis of molecular pathways involving ADMA, AGE, and TMAO in the context of atherosclerosis and organ damage.
• Synthesis of information on the correlation between rising toxin levels and worsening CKD.

Main Results:

• Uremic toxins such as ADMA, AGE, and TMAO are retained in CKD, promoting atherosclerosis and CVD.
• ADMA influences CVD through nitric oxide regulation, reactive oxygen species, and renal anemia.
• AGE accumulation and RAGE interaction cause cellular damage, while TMAO promotes organ fibrosis, both contributing to CVD.

Conclusions:

• Uremic toxins play a significant pathological role in the cardiorenal syndrome, exacerbating damage in both heart and kidney.
• Understanding the molecular mechanisms of these toxins is vital for developing strategies to prevent cardiorenal syndrome.
• Further research into the mutual relationships between uremic toxins may offer novel therapeutic targets.